In-depth analysis: cloudy prospects from potential price cuts Raised FY22F/23F earnings by 35%/70% and TP by 50%; upgrade to HOLD to factor in sales volume increase driven by release of favourable polices in 1Q22  Threatened by intensifying competition for concentrated Chinese medicines granules segment (CCMG, 69% of FY21 sales) with competitors increased from 4 in […]

Read more of this post